Compound 2, recognized as the first highly selective MET inhibitor, has been granted approval for the treatment of metastatic NSCLC associated with MET exon 14 skipping mutations (Wolf et al., 2020). This evidence concerns the gene MET and non-small cell lung carcinoma.